• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

20.86 +0.29 (+1.41%)
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Assembly Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
September 19, 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
August 09, 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
July 17, 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection ↗
July 21, 2022
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
July 14, 2023
 
Via Benzinga
News headline image
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
June 21, 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 07, 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
May 23, 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
May 04, 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
April 18, 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
April 03, 2023
 
Via Benzinga
News headline image
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
March 22, 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
February 15, 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs ↗
December 19, 2022
Assembly Biosciences Inc (NASDAQ: ASMB) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334). 
Via Benzinga
News headline image
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
December 19, 2022
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
November 14, 2022
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
November 08, 2022
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
November 04, 2022
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
NVIDIA To $140? Plus This Analyst Cuts PT On Assembly Biosciences By 82% ↗
October 24, 2022
  Truist Securities cut the price target on Assembly Biosciences, Inc. (NASDAQ: ASMB) from $11 to $2. Assembly Biosciences shares gained 2.6% to trade at $1.58 on Monday. 
Via Benzinga
News headline image
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
October 24, 2022
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor
October 05, 2022
Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board 
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022 ↗
October 24, 2022
Upgrades 
Via Benzinga
News headline image
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners ↗
July 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
7 Penny Stocks That Could Triple in 2022 ↗
June 22, 2022
Penny stocks are affordable and some with credible business models in all likelihood have the potential to generate superior returns. 
Via InvestorPlace
News headline image
Assembly Bio Commences Early-Stage Study of Drug to Treat Hepatitis B Viral Infection ↗
June 06, 2022
Assembly Biosciences, Inc. (NASDAQ: ASMB) today announced Initiation of Phase 1b clinical study of its drug candidate ABI-H3733 for Chronic Hepatitis B Virus Infection 
Via Benzinga
News headline image
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine ↗
May 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company ↗
April 30, 2022
I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings... 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
November 25, 2021
Gainers XTL Biopharmaceuticals (NASDAQ:XTLB 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
November 24, 2021
Gainers iSpecimen (NASDAQ:ISPC) shares in... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
October 06, 2021
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap